Kjeldsen S - Search Results

1

A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients.

Svensson-Färbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, Hedner T, Melander O. Svensson-Färbom P, et al. Among authors: kjeldsen s. J Hypertens. 2011 Feb;29(2):388-95. doi: 10.1097/HJH.0b013e3283410390. J Hypertens. 2011. PMID: 21052022 Clinical Trial.

2

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Dahlöf B, et al. Among authors: kjeldsen s. Am J Hypertens. 1997 Jul;10(7 Pt 1):705-13. Am J Hypertens. 1997. PMID: 9234823 Clinical Trial.

3

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H. Zanchetti A, et al. Among authors: kjeldsen s. J Hypertens. 2001 Jun;19(6):1149-59. doi: 10.1097/00004872-200106000-00021. J Hypertens. 2001. PMID: 11403365 Clinical Trial.

4

Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study.

Kjeldsen SE, Hedner T, Syvertsen JO, Lund-Johansen P, Hansson L, Lanke J, Lindholm LH, De Faire U, Dahlöf B, Karlberg BE; NORDIL Study Group. Kjeldsen SE, et al. J Hypertens. 2002 Jun;20(6):1231-7. doi: 10.1097/00004872-200206000-00038. J Hypertens. 2002. PMID: 12023696 Clinical Trial.

5

Comparison of home and office blood pressure in treated hypertensives in the Nordic Diltiazem (NORDIL) Study.

Kjeldsen SE, Hedner T, Syvertsen JO, Lund-Johansen P, Hansson L; NORDIL Group. Nordic Diltiazem. Kjeldsen SE, et al. Blood Press. 2002;11(6):371-6. doi: 10.1080/080370502321095348. Blood Press. 2002. PMID: 12523681 Free article.

6

Contrasting messages but not contradicting results from ALLHAT and ANBP2.

Hedner T, Himmelmann A, Kjeldsen SE. Hedner T, et al. Blood Press. 2003;12(2):68-9. doi: 10.1080/08037050310004658. Blood Press. 2003. PMID: 12797626 Free article. No abstract available.

7

In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?

Kjeldsen SE, Hedner T, Himmelman A. Kjeldsen SE, et al. Blood Press. 2003;12(3):132-3. doi: 10.1080/08037050310008005. Blood Press. 2003. PMID: 12875472 Free article. No abstract available.

8

Recent hypertension guidelines: JNC-7 and 2003 ESH/ESC.

Himmelmann A, Kjeldsen SE, Hedner T. Himmelmann A, et al. Blood Press. 2003;12(4):196-7. doi: 10.1080/08037050310015854. Blood Press. 2003. PMID: 14596354 Free article. No abstract available.

9

Masked hypertension--a new entity and challenge for clinical hypertension research and management.

Hedner T, Himmelmann A, Kjeldsen SE. Hedner T, et al. Blood Press. 2003;12(5-6):261-3. doi: 10.1080/08037050310025178. Blood Press. 2003. PMID: 14763655 Free article. No abstract available.

10

Cardiovascular risk stratification: an important tool for treatment to lower cardiovascular disease risk.

Himmelmann A, Kjeldsen S, Hedner T. Himmelmann A, et al. Among authors: kjeldsen s. Blood Press. 2004;13(3):125-6. doi: 10.1080/08037050410015088. Blood Press. 2004. PMID: 15223719 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

848 results

Search Page

Filters